The Mechanism of Anti-Viral Activity of a Novel, Hydroponically Selenium-Enriched Garlic Powder (SelenoForce®) Against SARS-CoV-2 Virus
- PMID: 39130207
- PMCID: PMC11311149
- DOI: 10.1177/27536130241268100
The Mechanism of Anti-Viral Activity of a Novel, Hydroponically Selenium-Enriched Garlic Powder (SelenoForce®) Against SARS-CoV-2 Virus
Abstract
Abstract: The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is far from over as new strains are emerging all over the world. Selenium as a micronutrient is important for immunity and also has anti-viral activity.
Objective: The study evaluated the activity of a Selenium enriched garlic powder (SeGP or SelenoForce®) against SARS-CoV-2 viral replication in vitro and explored its possible mechanism of action.
Methods: The anti-SARS-CoV-2 activity assay was carried out in Vero E6 cells in vitro. Human lung carcinoma A549 cells were used to study the antioxidant activity, expression of angiotensin converting enzyme (ACE), transmembrane protease, serine 2 (TMPRSS2) and the activity of proprotein convertase, and furin. Anti-inflammatory activity was evaluated in lipopolysaccharide-activated RAW 264.7 cells.
Results: SeGP inhibited the replication of SARS-CoV-2 in Vero E6 cells with an IC50 of 19.59 μg/ml. It exhibited significant antioxidant activity in vitro with IC50 value determined as 43.45 μg/ml. The Selenium enriched product inhibited the expression of ACE and TMPRSS2 and also showed inhibition of furin protease activity. In the presence of SeGP, the secretion of nitric oxide, interleukin -6 and TNF-α were reduced in activated RAW 264.7 macrophages.
Conclusion: The results of the study suggest that Selenium enriched garlic powder could inhibit SARS-CoV-2 multiplication in vitro, reduce oxidative stress and inflammatory mediators suggesting that it could be developed as an effective supplement or adjunct therapy to combat viral infections.
Keywords: SARS-CoV-2; inflammation; micronutrient; oxidative stress; selenium.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All the authors are employees of Sami-Sabinsa Group Limited or Sabinsa Corporation, which markets SelenoForce®.
Figures
Similar articles
-
Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.Int J Mol Sci. 2022 Oct 19;23(20):12522. doi: 10.3390/ijms232012522. Int J Mol Sci. 2022. PMID: 36293378 Free PMC article.
-
Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.J Virol. 2022 Apr 27;96(8):e0012822. doi: 10.1128/jvi.00128-22. Epub 2022 Mar 28. J Virol. 2022. PMID: 35343766 Free PMC article.
-
Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice.Phytomedicine. 2023 Jul 25;116:154858. doi: 10.1016/j.phymed.2023.154858. Epub 2023 May 5. Phytomedicine. 2023. PMID: 37224774 Free PMC article.
-
Mechanics Insights of Alpha-Lipoic Acid against Cardiovascular Diseases during COVID-19 Infection.Int J Mol Sci. 2021 Jul 26;22(15):7979. doi: 10.3390/ijms22157979. Int J Mol Sci. 2021. PMID: 34360751 Free PMC article. Review.
-
Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?Front Immunol. 2020 May 28;11:1229. doi: 10.3389/fimmu.2020.01229. eCollection 2020. Front Immunol. 2020. PMID: 32574272 Free PMC article. Review.
References
-
- Kitazato K, Wang Y, Kobayashi N. Viral infectious disease and natural products with antiviral activity. Drug Discov Ther. 2007;1(1):14-22. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous